Early changes in PSA and association with outcomes in mCRPC patients.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5063
Abstract: 5063Background: Declines in prostate specific antigen (PSA) levels at 12-weeks are currently used to evaluate treatments response in metastatic castration resistant prostate cancer (mCRPC). Early P... read more here.
Keywords: association outcomes; outcomes mcrpc; mcrpc patients; psa association ... See more keywords